Leap Investments’s Corcept Therapeutics CORT Stock Holding History

Leap Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-29,933	Closed	-$362K	–	391
2019 Q4	$362K	Buy	+29,933	New	+$417K	0.17%	206

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Leap Investments's CORT Position: Q1 2020 in Review

Leap Investments sold out of Corcept Therapeutics (CORT) in Q1 2020, closing a stake of 29,933 shares — an estimated $362K sold.

Leap Investments first reported a position in CORT in Q4 2019 and held it in 1 quarter. The position peaked at $362K in Q4 2019. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

Leap Investments reported no remaining Corcept Therapeutics position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 29,933 Corcept Therapeutics shares in Q1 2020, an estimated $362K.
Leap Investments first reported a position in Corcept Therapeutics in Q4 2019 and held it in 1 quarter.
Leap Investments's Corcept Therapeutics position peaked at $362K in Q4 2019.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.